Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 23 is a protein encoded by the ZNF23 gene in humans. It is a C2H2-type zinc finger transcription factor thought to enable sequence-specific double-stranded DNA binding and participate in the regulation of transcription by RNA polymerase II. ZNF23 may also have a role in embryonic development, and is predicted to be active in the nucleus[1][2][6]. ZNF23 is not currently considered a therapeutic target (such as a receptor, enzyme, transporter, etc.), and there are no known drugs, biomarkers, safety concerns, or well-established disease associations from the current literature[1][6]. Its principal biological role is inferred from protein family classification and gene ontology annotations as a transcriptional regulator, rather than as a classical druggable target[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 23 (ZNF23).